Pharmakotherapie der ventrikulären rhythmusstörungen. Was kommt, was bleibt, was geht?

Translated title of the contribution: Pharmacological therapy for ventricular arrhythmias: Evidence for current treatment strategies and perspectives for the future

F. T. Wegener, G. C. Grönefeld, G. Duray, J. R. Ehrlich, S. H. Hohnloser

Research output: Contribution to journalReview article


This review summarizes the current status of pharmacological therapy for ventricular arrhythmias in symptomatic patients. The selection of specific drugs for this indication is highly dependent on the underlying heart disease. In primary prevention of sudden death, antiarrhythmic agents do not play a role - except betareceptor antagonists. Similarly, in patients treated for secondary prevention of cardiac arrest or hemodynamically symptomatic ventricular tachycardia, the implantable defibrillator constitutes the therapy of choice with hardly any role left for antiarrhythmic drugs. An emerging role for antiarrhythmic drug therapy is represented by the concomitant pharmacological treatment in ICD recipients who experience shocks from their devices (hybrid therapy). Several randomized clinical trials have recently evaluated this issue and permit an evidence-based treatment strategy. Currently, most patients receive sotalol or amiodarone for hybrid therapy with azimilide as a potential new class III antiarrhythmic drug for this treatment indication.

Original languageGerman
Pages (from-to)297-307
Number of pages11
Issue number3
Publication statusPublished - Mar 1 2006



  • Antiarrhythmics
  • Hybrid therapy
  • Implantable cardioverter defibrillator
  • Sudden cardiac death
  • Ventricular arrhythmia

ASJC Scopus subject areas

  • Internal Medicine

Cite this